Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gala Health vs Enhance MD

Gala Health
Graded #8

Higher grade

vs+1
Enhance MD
Graded #13

Lower grade

The verdict

Gala Health takes it — 86/100 to 85/100, but only just.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier. Enhance MD is close behind and may still be the better fit — see the factor split below.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +8
90
82
Dose & formulationGala Health +1
83
82
Clinical oversightEnhance MD +3
85
88
Labs & monitoringEnhance MD +7
83
90
FulfillmentGala Health +4
88
84
Contract termsGala Health +2
86
84
Gala Health · left barEnhance MD · right bar

The numbers

MetricGala HealthEnhance MD
WeighScore86/10085/100
GradeBB
Scorecard rank#8#13
SemaglutideNot disclosed$212/mo
Tirzepatide$179/mo$280/mo
CoverageAll 50 statesNot publicly listed
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Gala Health

Graded #8 · B

Strengths

  • Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
  • Available in all 50 states
  • Keeps a brand-name path open (Ozempic listed at $1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Enhance MD

Graded #13 · B

Strengths

  • Transparent tiered pricing across sema, tirz, microdose, and combo
  • Dose-flat — the price does not step up as you titrate
  • Six-month lab testing plus provider-led care
  • NAD+ longevity adjacency available

Where it loses points

  • Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
  • No oral or sublingual route
  • States served are not published
  • Higher entry price than the cheapest compounded programs

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard